eIF4F suppression in breast cancer affects maintenance and progression
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Levels of eukaryotic initiation factor 4E (eIF4E) are frequently elevated in human cancers and in some instances have been associated with poor prognosis and outcome. Here we utilize transgenic and allograft breast cancer models to demonstrate that increased mammalian target of rapamycin (mTOR) signalling can be a significant contributor to breast cancer progression in vivo. Suppressing mTOR activity, as well as levels and activity of the downstream translation regulators, eIF4E and eIF4A, delayed breast cancer progression, onset of associated pulmonary metastasis in vivo and breast cancer cell invasion and migration in vitro. Translation of vascular endothelial growth factor (VEGF), matrix metallopeptidase 9 (MMP9) and cyclin D1 mRNAs, which encode products associated with the metastatic phenotype, is inhibited upon eIF4E suppression. Our results indicate that the mTOR/eIF4F axis is an important contributor to tumor maintenance and progression programs in breast cancer. Targeting this pathway may be of therapeutic benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
Cencic, R., Carrier, M., Galicia-Vázquez, G., Bordeleau, M.-E., Sukarieh, R., Bourdeau, A., Brem, B., Teodoro, J. G., Greger, H., Tremblay, M. L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005223 · Cited by 302
Self-citationAmplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis
Andrechek, E. R., Hardy, W. R., Siegel, P. M., Rudnicki, M. A., Cardiff, R. D., & Muller, W. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3444 · Cited by 230
c-Myc and eIF4F Are Components of a Feedforward Loop that Links Transcription and Translation
Lin, C.-J., Cencic, R., Mills, J. R., Robert, F., & Pelletier, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5876 · Cited by 180
Self-citation
Cited by
Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2789 · Cited by 367
“The prevailing data from these studies indicate that the oncogenic effects of eIF4E are a result of activated eIF4F rather than a unique function of eIF4E overexpression (122, 123).”
BackgroundSelf-citationTranslational Control in Cancer
Robichaud, N., Sonenberg, N., Ruggero, D., & Schneider, R. J. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a032896 · Cited by 302
The plasticity of mRNA translation during cancer progression and therapy resistance
Fabbri, L., Chakraborty, A., Robert, C., & Vagner, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00380-y · Cited by 276
Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3
Robichaud, N., del Rincon, S. V., Huor, B., Alain, T., Petruccelli, L. A., Hearnden, J., Goncalves, C., Grotegut, S., Spruck, C. H., Furic, L., et al. (2015) · Oncogene · doi:10.1038/onc.2014.146 · Cited by 259
Self-citationRubio, C. A., Weisburd, B., Holderfield, M., Arias, C., Fang, E., DeRisi, J. L., & Fanidi, A. (2014) · Genome Biology · doi:10.1186/s13059-014-0476-1 · Cited by 200
“found that eIF4F inhibition impaired cell migration in highly metastatic TM15 breast cancer cells [26].”
BackgroundCuesta, R., & Holz, M. K. (2016) · Oncotarget · doi:10.18632/oncotarget.8375 · Cited by 37
“Deregulation of eIF4F activity results in increased translation of mRNAs that code for proteins involved in cellular growth and proliferation, survival, and migration, and consequently contributes to tumor development and progression [28, 41].”
Background
Metadata
- Authors
- Nasr, Z., Robert, F., Porco, J. A., Muller, W. J., & Pelletier, J.
- Venue
- Oncogene
- Published
- 2012-04-09
- Volume
- 32
- Issue
- 7
- Pages
- 861-871
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2051430639
- Cited by
- 81
- References
- 3
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.